New, non-adenosine, high-potency agonists for the human adenosine A2B receptor with an improved selectivity profile compared to the reference agonist n-ethylcarboxamidoadenosine

被引：140

作者：

Beukers, MW ^{[1
]}

Chang, LCW ^{[1
]}

Künzel, JKVD ^{[1
]}

Mulder-Krieger, T ^{[1
]}

Spanjersberg, RF ^{[1
]}

Brussee, J ^{[1
]}

Ijzerman, AP ^{[1
]}

机构：

[1] Gorlaeus Labs, LACDR, Div Med Chem, NL-2300 RA Leiden, Netherlands

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2004年 / 47卷 / 15期

关键词：

D O I：

10.1021/jm049947s

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The adenosine A(2B) receptor is the least well characterized of the four known adenosine receptor subtypes because of the absence of potent, selective agonists. Here, we present five non-adenosine agonists. Among them, 2-amino-4-(4-hydroxyphenyl)-6-(1H-imidazol-2-ylmethylsulfanyl)pyridine-3,5.-dicarbonitrile, 17, LUF5834, is a high-efficacy partial agonist with EC50 = 12 nM and 45-fold selectivity over the adenosine A(3) receptor but lacking selectivity versus the A, and A(2A) subtypes. Compound 18, LUF5835, the 3-hydroxyphenyl analogue, is a full agonist with EC50 = 10 nM.

引用

页码：3707 / 3709

页数：3

共 7 条

[1] 2-Substituted N-ethylcarboxamidoadenosine derivatives as high-affinity agonists at human A3 adenosine receptors
Klotz, KN
Camaioni, E
Volpini, R
Kachler, S
Vittori, S
Cristalli, G
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1999, 360 (02) : 103 - 108
[2] 2-Substituted N-ethylcarboxamidoadenosine derivatives as high-affinity agonists at human A3 adenosine receptors
K.-N. Klotz
E. Camaioni
R. Volpini
S. Kachler
S. Vittori
G. Cristalli
Naunyn-Schmiedeberg's Archives of Pharmacology, 1999, 360 : 103 - 108
[3] MEDI 437-Structure-activity relationships of 2, N6, 5'-substituted adenosine derivatives as human A2B adenosine receptor agonists
Adachi, Hayamitsu
Palaniappan, Krishnan K.
Gao, Zhan-Guo
Jacobson, Kenneth A.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 232
[4] The aminopyridine-3,5-dicarbonitrile core for the design of new non-nucleoside-like agonists of the human adenosine A2B receptor
Betti, Marco
Catarzi, Daniela
Varano, Flavia
Falsini, Matteo
Varani, Katia
Vincenzi, Fabrizio
Ben Diego, Dal
Lambertucci, Catia
Colotta, Vittoria
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 150 : 127 - 139
[5] Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) having high potency at the human A2B and A3 receptor subtypes
Kim, YC
de Zwart, M
Chang, L
Moro, S
Kunzel, JKVD
Melman, N
IJzerman, AP
Jacobson, KA
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (15) : 2835 - 2845
[6] N6-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A3 receptor and a starting point for searching A2B ligands
Volpini, R
Costanzi, S
Lambertucci, C
Taffi, S
Vittori, S
Klotz, KN
Cristalli, G
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (15) : 3271 - 3279
[7] N6-[(Hetero)aryl/(cyclo)alkyl-carbamoyi-methoxy-phenyl]-(2chloro)-5′-N-ethylearboxamido-adenosines:: The first example of adenosine-related structures with potent agonist activity at the human A2B adenosine receptor
Baraldi, Pier Giovanni
Preti, Delia
Tabrizi, Mojgan Aghazadeh
Fruttarolo, Francesca
Saponaroa, Giulia
Baraldi, Stefania
Romagnoli, Romeo
Moorman, Allan R.
Gessi, Stefania
Varani, Katia
Borea, Pier Andrea
BIOORGANIC & MEDICINAL CHEMISTRY, 2007, 15 (07) : 2514 - 2527

← 1 →